A Life-Saving Drug’s Race to America
For people living with hereditary angioedema (HAE), a devastating rare disease that causes severe swelling in many parts of the body, there has been no treatment available in America. Until now.
A small biotech set out to bring Cinryze — an HAE drug previously approved in Europe — to America. Initially, however, the trial did not go as planned.
The first large CRO that managed the trial had 100% CRA turnover, resulting in damaged relationships with key sites. Recruitment stalled.
The ARG Solution:
ARG deployed experienced and strategic CRAs. ARG’s approach empowered CRAs on the frontlines of clinical sites to proactively solve novel problems, establish meaningful face-to-face relationships with study coordinators, and spend extra time answering questions. The ARG difference accelerated recruitment and guaranteed the success of this pivotal study — with a 0% CRA turnover rate.